+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Short Bowel Syndrome (SBS) - Global Strategic Business Report

  • PDF Icon

    Report

  • 194 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309856
The global market for Short Bowel Syndrome (SBS) was estimated at US$1.6 Billion in 2023 and is projected to reach US$6.4 Billion by 2030, growing at a CAGR of 21.6% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Short Bowel Syndrome (SBS) Market - Key Trends and Drivers Summarized

Why Is the Short Bowel Syndrome (SBS) Market Gaining Attention in the Healthcare Industry?

The Short Bowel Syndrome (SBS) market is gaining attention in the healthcare industry due to the rising incidence of gastrointestinal disorders and the increasing need for effective management of SBS, a condition characterized by inadequate nutrient absorption due to surgical removal of a significant portion of the small intestine. Patients with SBS face challenges such as malnutrition, dehydration, diarrhea, and dependence on parenteral nutrition (PN) or enteral nutrition (EN) support, making comprehensive management essential. The growing focus on improving patient outcomes, quality of life, and reducing long-term healthcare costs is driving the demand for innovative therapies, including pharmacological treatments, nutritional support, and surgical interventions, in the management of SBS.

How Are Technological Advancements and New Therapies Transforming the SBS Market?

Technological advancements and new therapies are significantly transforming the SBS market by enhancing the efficacy, safety, and convenience of SBS management. The development of novel pharmacological treatments, such as glucagon-like peptide-2 (GLP-2) agonists, growth hormones, and enzyme replacements, is improving intestinal adaptation, absorption, and fluid retention, reducing the need for parenteral nutrition and hospital visits. The emergence of personalized, multidisciplinary, and nutrition-based care models, supported by telemedicine, remote monitoring, and digital health platforms, is enabling more tailored and patient-centric approaches to SBS management. Additionally, advancements in regenerative medicine, gene therapy, and microbiome-based treatments are opening new frontiers in SBS research, offering the potential for long-term solutions and reduced complications.

Which Market Segments Are Leading the Adoption of SBS Therapies?

Treatment types include parenteral nutrition (PN), enteral nutrition (EN), pharmacological therapies, and surgical interventions, with PN and pharmacological therapies being the most widely adopted due to their critical role in providing essential nutrients, fluids, and managing symptoms. Patient types encompass pediatric, adult, and post-surgical SBS patients, with pediatric and post-surgical segments leading the market due to the high prevalence of congenital, post-surgical, and acquired SBS conditions. Distribution channels include hospitals, specialty clinics, retail pharmacies, and home healthcare, with hospitals and specialty clinics being the largest segments due to the need for specialized care, monitoring, and support. Asia-Pacific is emerging as a high-growth region driven by improving healthcare infrastructure and rising incidence of gastrointestinal disorders.

What Are the Key Drivers of Growth in the Short Bowel Syndrome (SBS) Market?

The growth in the Short Bowel Syndrome (SBS) market is driven by several factors, including the rising incidence of SBS and other gastrointestinal disorders, technological advancements in parenteral nutrition, enzymes, and pharmacological treatments, and the increasing use of human growth hormone, glucagon-like peptide-2 (GLP-2) agonists, and dietary supplements in SBS management. The development of orphan drugs, biologics, and novel surgical techniques with enhanced efficacy, safety, and convenience is driving market adoption among hospitals, specialty clinics, and home healthcare providers. The focus on enhancing multidisciplinary, patient-centric care models, self-management, and remote monitoring is expanding the market reach among pediatric, adult, and post-surgical patients. The growing use of SBS therapies in combination with regenerative medicine, digital health, and artificial intelligence, coupled with the demand for personalized and nutrition-based SBS care solutions, is creating new opportunities for market growth. Additionally, the increasing investments in R&D for gene therapy, stem cell therapy, and microbiome-based treatments are further supporting market expansion.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the GLP-2 Drugs segment, which is expected to reach US$5.4 Billion by 2030 with a CAGR of a 23.3%. The Growth Hormone segment is also set to grow at 21.0% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was estimated at $444.6 Million in 2023, and China, forecasted to grow at an impressive 20.2% CAGR to reach $934.2 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Short Bowel Syndrome (SBS) Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Short Bowel Syndrome (SBS) Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Short Bowel Syndrome (SBS) Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Ardelyx, Inc., Emmaus Life Sciences, Inc., Merck KgaA, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 42 Featured):

  • Ardelyx, Inc.
  • Emmaus Life Sciences, Inc.
  • Merck KgaA
  • Naia Pharmaceuticals Inc.
  • Nutrien Ltd.
  • OxThera AB
  • Shire PLC
  • Zealand Pharma A/S

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Short Bowel Syndrome (SBS) - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Short Bowel Syndrome (SBS) and Other Gastrointestinal Disorders Spurs Market for SBS Therapies
  • Technological Advancements in Parenteral Nutrition, Enzymes, and Pharmacological Treatments Propel Innovation in SBS Management
  • Increasing Use of Human Growth Hormone, Glucagon-Like Peptide-2 (GLP-2) Agonists, and Dietary Supplements Expands Addressable Market Opportunity
  • Growth of Home Healthcare, Specialty Clinics, and Telemedicine Strengthens Business Case for SBS Treatments
  • Focus on Enhancing Efficacy, Safety, and Convenience of SBS Therapies Drives Adoption in Healthcare Systems
  • Emergence of Orphan Drugs, Biologics, and Novel Surgical Techniques Generates New Market Opportunities
  • Rising Demand for Personalized, Multidisciplinary, and Nutrition-Based SBS Care Models Boosts Market Potential
  • Shift Towards Patient-Centric Approaches, Self-Management, and Remote Monitoring Expands Market Reach
  • Growing Emphasis on Preventing and Managing SBS-Related Complications, Infections, and Malabsorption Spurs Market Innovation
  • Focus on Developing SBS Solutions for Pediatric, Adult, and Post-Surgical Patients Strengthens Market Position
  • Rising Use of SBS Therapies in Combination with Regenerative Medicine, Digital Health, and Artificial Intelligence Creates New Opportunities
  • Expansion of SBS Applications in Clinical Trials, Patient Advocacy, and Healthcare Reimbursement Drives Market Growth
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Short Bowel Syndrome (SBS) Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Short Bowel Syndrome (SBS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Short Bowel Syndrome (SBS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for GLP-2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for GLP-2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for GLP-2 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Growth Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Growth Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Growth Hormone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Glutamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Glutamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Glutamine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 21: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 22: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 23: USA Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 24: USA Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 25: USA 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 26: USA Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 27: USA Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 28: USA 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
CANADA
  • Table 29: Canada Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 30: Canada Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 31: Canada 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 32: Canada Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 33: Canada Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 34: Canada 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
JAPAN
  • Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 35: Japan Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 36: Japan Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 37: Japan 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 38: Japan Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 39: Japan Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 40: Japan 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
CHINA
  • Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 41: China Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 42: China Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 43: China 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 44: China Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 45: China Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 46: China 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
EUROPE
  • Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 47: Europe Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 48: Europe Historic Review for Short Bowel Syndrome (SBS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 49: Europe 16-Year Perspective for Short Bowel Syndrome (SBS) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 50: Europe Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 51: Europe Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 52: Europe 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 53: Europe Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 54: Europe Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 55: Europe 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
FRANCE
  • Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 56: France Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 57: France Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 58: France 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 59: France Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 60: France Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 61: France 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
GERMANY
  • Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 62: Germany Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 63: Germany Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 64: Germany 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 65: Germany Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 66: Germany Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 67: Germany 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
ITALY
  • Table 68: Italy Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 69: Italy Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 70: Italy 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 71: Italy Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 72: Italy Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 73: Italy 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 74: UK Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 75: UK Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 76: UK 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 77: UK Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 78: UK Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 79: UK 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 80: Rest of Europe Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 81: Rest of Europe Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 82: Rest of Europe 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 83: Rest of Europe Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 84: Rest of Europe Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 85: Rest of Europe 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 86: Asia-Pacific Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 87: Asia-Pacific Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 88: Asia-Pacific 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 89: Asia-Pacific Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 90: Asia-Pacific Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 91: Asia-Pacific 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
REST OF WORLD
  • Table 92: Rest of World Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 93: Rest of World Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 94: Rest of World 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 95: Rest of World Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 96: Rest of World Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 97: Rest of World 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Ardelyx, Inc.
  • Emmaus Life Sciences, Inc.
  • Merck KgaA
  • Naia Pharmaceuticals Inc.
  • Nutrien Ltd.
  • OxThera AB
  • Shire PLC
  • Zealand Pharma A/S

Table Information